| Literature DB >> 34031516 |
Boualem Sendid1, Karine Lecointe2, Mayeul Collot3, Pierre-Marie Danzé4, Sébastien Damiens2, Anne-Sophie Drucbert4, Chantal Fradin5, Jean-Pierre Vilcot6, Frédéric Grenouillet7, Faustine Dubar2, Jérôme de Ruyck2, Samir Jawhara2, Jean-Maurice Mallet3, Daniel Poulain8.
Abstract
Candida albicansEntities:
Year: 2021 PMID: 34031516 PMCID: PMC8144402 DOI: 10.1038/s41598-021-90402-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Multi-analyte profiling (MAP) analysis of biotin sulfone tagged synthetic oligomannoside (BTSO) reactivity with anti-carbohydrate monoclonal antibodies (MAbs). Results are shown as the mean fluorescence intensity obtained with MAbs (EB-CA1: black bars; 5B2: grey bars; and B6.1: hatched bars), or EB-A2 (white bars) for each microbead set coated with different BSTOs including α-1,2-mannobioside (2α-Man), α-1,2-mannotetraose (4α-Man), β-1,2-mannobioside (2β-Man), β-1,2-mannotriose (3β-Man), and β-1,2-mannotetraose (4β-Man).
Figure 2Surface plasmon resonance analysis of biotin sulfone tagged synthetic oligomannoside (BSTO) reactivity with anti-carbohydrate monoclonal antibodies (MAbs). MAbs B6.1 (orange curve), 5B2 (blue curve), EB-CA1 (yellow curve), and control (EB-A2, grey curve) were successively tested with 2α-Man (a), 2β-Man (b), 3β-Man (c), 4α-Man (d), and 4β-Man (e).
Figure 3Western blots of whole cell extracts from C. albicans serotype A (VW32, BWP17 and bmt6Δ) and serotype B (NIH B-792) strains probed with MAbs B6.1 and EB-CA1. The insert shows a serotype A strain (BWP17) and serotype B strain (NIHB) probed with MAb 5B2 showing the shift in rMW previously characterized structurally, and resulting from shortening of β-Man chain to 3 mannose residues in serotype B strains[34].
Figure 4Reactivity of human sera against C. albicans mannan and BSTO. Reactivity against C. albicans mannan (a) as detected by ELISA (Platelia Candida Ab test), and against BST-3β-Man (b), as detected by multi-analyte profiling (MAP) analysis. Human sera consisted of sera from healthy controls (blood donors presenting no disease), and ICU patients either not-infected or infected with C. albicans. Anti-C. albicans mannan antibody response is shown for infected patients according to antigenemia status (negative: open symbols; positive: closed symbols) (b). The correlation between anti-mannan and 2α-Man, 2β-Man, 3β-Man antibodies is shown in (c, d, e) respectively. The values of Spearman rank correlation coefficients for the different BSTOs are given in f.
Figure 5Reactivity of human sera against 2α-Man, 2-β-Man, and establishment of 2β-Man/2α-Man ratio for differentiation between uninfected and infected ICU patients. (a) 2α-Man, (b) 2β-Man and (c) 2βMan/2α-Man ratio (open squares: negative mannanemia; closed squares positive mannanemia). (d) Statistical analysis of the ability of different antigens to discriminate between study groups.
Figure 6Affinity curves for recombinant mannose-binding lectin (rMBL) binding to oligomannosides. (a) Typical sensorgram of the interaction of MBL with 3β-Man (2 mM). (b) Normalized affinity curves of increasing mM of the different oligomannosides with MBL.
Information and references for the antigens used in the study and the technology involved in their analysis.
| Antigens/Epitopes | References | Main characteristics | Analytical methods | ||
|---|---|---|---|---|---|
| Synthetic | Multianalysis profiling | Surface plasmon resonance | Western Blotting/ELISA*** | ||
| Manα-1,2Man | X | X | X | ||
| Manα-1,2Manα-1,2Manα-1,2Man | X | ||||
| Manβ-1,2Man | X | ||||
| Manβ-1,2Manβ-1,2Man | Mat & Meths | Synthesized for the present study | X | ||
| Manβ-1,2Manβ-1,2Manβ-1,2Man | X | X | X | ||
From | [ | Complex cell wall surface polymer. Structure determined by NMR and sequential depolymerization of constitutive oligomannosides used for diagnostic purposes | *** | ||
| [ | Glycoplipid of the mannoinositolphospho ceramide family Present at cell wall surface Shed in contact with host cells and has immunomodulatory properties | X | |||
| From | [ | Polysaccharide moiety consisting of β-mannosides up to 14 residues | X | ||
| From | [ | Polysaccharide moiety consisting of β-1,2 mannotriose | X | ||
| From | [ | PLM identical to that of VW32. Used for genetic manipulations | X | ||
| From | [ | Polysaccharide moiety truncated with a β-mannotriose | X | ||
Information about antibodies/probes used in the study and technology involved in their analysis.
| Probes | Analytical method | References | ||
|---|---|---|---|---|
| Multiple analysis profiling | Surface plasmon resonance | Western blotting | ||
| 5B2 | [ | |||
| EB-CA1 | [ | |||
| B6.1 | [ | |||
| EB-A2 | [ | |||
| Polyclonal antibodies from healthy individuals | [ | |||
| Polyclonal antibodies from colonized patients | ||||
| Polyclonal antibodies from infected patients | ||||
Figure 7Synthesis of biotinylated β (1 → 2) mannotriose. Compound 6 (tribeta) was prepared in four steps from 1[10] using coupling and deprotection protocols employed for related di- and tetramannosides[62]. Reagents and conditions: (a) NaOH, THF, 60 °C, 98%; (b) DMAP, EDC CH2Cl2, RT 47%; (c) meta chloro perbenzoic acid, CH2Cl2, room temperature, 87%; (d) H2, Pd/C, MeOH, 87%. In the following Figs. 2, 3, 5, 6 and 7 oligomannosides are designated by acronyms referring to the number of residues and the anomery (i.e. 3β-Man for β-mannotriose) and presented with the color codes already used in studies on oligomannose synthesis (i.e. red for α anomery and green for β anomery[17]), and the main topic of this study, 3β-Man, is represented in darker green.